Anti-Mouse CD8a Monoclonal Antibodies

Background

The rat anti-mouse CD8a monoclonal antibody 53-6.72  (rat IgG2a kappa) reacts with the mouse CD8a protein (T-cell surface glycoprotein CD8 alpha chain) encoded by the mouse CD8A gene that encodes the CD8a chain of the dimeric CD8 protein. The mouse CD8 protein is primarily responsible for cell-mediated immune defense and T-cell development. CD8A has been widely reported as a potential prognosis and diagnostic marker for several diseases, such as inflammatory disorders and tumors. It was shown that the anti-mouse CD8a rat monoclonal antibody (clone number: 53-6.72) can be used for depleting activity in vivo.

Our recombinant 53-6.72 antibodies have a part (variable regions) or complete amino acid sequences of the rat anti-mouse CD8a monoclonal antibody (hybridoma clone name or number: 53-6.72).

PA007533.r2a: In Vivo Grade Recombinant Anti-mouse CD8a Monoclonal Antibody (Clone: 53-6.72), Rat IgG2a Kappa

Recombinant rat IgG2a Monoclonal Antibody.
Clone: 53-6.72.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD8a monoclonal antibody (clone: 53-6.72) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: 53-6.72) specifically binds to mouse CD8a.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD8a protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse CD8a monoclonal antibody of clone 53-6.72 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of anti-mouse CD8a antibody (53-6.72)

Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors Plus MEK Inhibitors in Melanoma.
Teh JL, et al. (2020). Cancer Immunol Res. 2020 Sep;8(9):1135-1147. doi: 10.1158/2326-6066.CIR-19-0743. PMID: 32661093
To deplete CD8 + T cells, mice were treated with 300 ?g of anti-CD8 ? (clone 53-6.72) every 3 days for the duration of the experiment, starting 2 days before tumor implantation. D4M3.A cells were injected into either immune-compromised NOD-scid ? (NSG) mice or immunocompetent syngeneic C57BL/6 mice. Tumors were removed and dissociated into single cell suspensions. Human melanoma cell lines were treated with DMSO, MEKi (PD0325901, 5 nM), CDK4/6i (palbociclib, 0.5 ?M), or MEKi plus CDK4/6i for 48 hours. C57BL/6 mice were depleted of CD8 cells by intraperitoneal injection of CD8 ? (clone 53-6.72) antibody three days prior to intradermal implantation of D4M3.A cells.
Tags: anti-mouse CD8a 53-6.72; anti-mouse CD8a 53-6.72 mAb

Hepatic Natural Killer T-cell and CD8+ T-cell Signatures in Mice with Nonalcoholic Steatohepatitis.
Bhattacharjee J, et al. (2017). Hepatol Commun. 2017 Jun;1(4):299-310. doi: 10.1002/hep4.1041. PMID: 29152605
Briefly, C57Bl6/J mice fed an HFHC diet for 12 weeks were subjected to intraperitoneal injection of anti?CD8 (clone 53?6.72) monoclonal antibodies (mAbs) (200 mg/kg) every 3 days until 16 weeks of the HFHC diet. Liver TG content was determined at 16 weeks post?HFHC diet as described. For detection of CD68?positive and CD11b?positive cells in the mice liver tissue, formalin?fixed liver tissues from mice were subjected to microtome sectioning to generate 5??m sections for immunohistochemistry. The 6?8?week?old C57Bl6/J/6J mice fed an HFHC diet for 16 weeks showed increased weight gain (28.12 ± 1.53 g HFHC wild type (WT) versus 10.01 ± 1.01 g Chow WT; Fig. 1A) and liver weight (2.44 ± 0.24 g HFHC WT versus 1.47 ± 0.02 g Chow WT; Fig. 1B). We fed 6?8?week?old CD1dKO mice an HFHC diet for 16 weeks.
Tags: anti-mouse CD8a 53-6.72 antibody in vivo; anti-mouse CD8a 53-6.72 in cancer research

Gammadelta T Cells in Anterior Chamber-Induced Tolerance in CD8+ Cytotoxic T Lymphocyte Responses.
Xu Y, et al. (2002). Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3505-11. doi: Not available. PMID: 12407158
OVA-specific lytic activity was mediated by CD8+ T cells because anti-CD8 mAb (53-6.72) blocked CTL activity when added to the in vitro activation culture or to the 4-hour lytic assay (data not shown). Mice were primed for OVA-CTL responses by injection of 200 ?g OVA in CFA into the rear footpad. Ten days later, their spleens were harvested and single-cell suspensions prepared. To determine whether CD8+ CTL development is subject to ocular tolerance, OVA-specific CTL responses were measured in B6 mice that were untreated or injected with 50 ?g OVA or KLH in the AC 7 days before SC immunization with 200 ?g OVA in CFA. The frequency of cytotoxic T-cell precursors (pTc) was determined by the classic limiting-dilution assay as described by Kruisbeek.
Tags: anti-mouse CD8a 53-6.72 in mouse tumor model; function of anti-mouse CD8a 53-6.72

A novel CD8-independent high-avidity cytotoxic T-lymphocyte response directed against an epitope in the phosphoprotein of the paramyxovirus simian virus 5.
Gray PM, et al. (2001). J Virol. 2001 Nov;75(21):10065-72. doi: 10.1128/JVI.75.21.10065-10072.2001. PMID: 11581375
To enumerate high- and low-avidity cells, titrated numbers of splenocytes were cultured in the presence or absence of anti-CD8 antibody (clone 53-6.72) in the form of ascites for 15 min at 37 °C. Responding BALB/c spleen cells (7.5 × 10^6) from mice previously immunized with wild-type SV5 intranasally (i.n.) were cocultured with 3.5 × 10^6 stimulating BALB/c splenocytes (UV inactivated) infected 20 h previously with wild-type SV5 at a multiplicity of infection (MOI) of 10. The 51Cr release assay was carried out as described previously (1) with modifications. Target cells (10^6) were labeled with 200 to 300 ?Ci of Na2 51CrO4 in 200 to 300 ?l of RPMI 1640 medium supplemented with 10% NCS and 10 mM HEPES for 2 h at 37 °C. To determine the proteins that were immunogenic, mice were immunized with WT rSV5 i.n., and on day 12 postimmunization, the splenocytes were harvested and used in ELISPOT assays.
Tags: bioactivity of anti-mouse CD8a 53-6.72; anti-mouse CD8a 53-6.72 of low endotoxin

Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells.
North RJ, et al. (1984). J Exp Med. 1984 Mar 1;159(3):574-87. doi: 10.1084/jem.159.3.574. PMID: 6232335
Hybridomas secreting monoclonal anti-Thy-1.2 (30-H12), anti-Ly-1 (53-7.313), and anti-Ly-2 (53-6.72) antibody (9) were obtained from the Salk Institute, La Jolla, CA. For each experiment a vial was thawed, the cells washed in PBS, and 2 × 10^6 of them used to initiate ascites tumors in CB6F1 mice. Passive transfer was performed at a single time with recipients bearing a standard-sized tumor. The results in Fig. 4 show that splenic T cells capable of adoptively immunizing against an established tumor were acquired between days 3 and 6 of tumor growth, reached peak numbers on day 9, and were rapidly lost over the next 3 d. It can be seen in Fig. 7 that the capacity of immune spleen cells to cause regression of an established tumor in TXB recipients was inhibited by passive transfer of spleen cells from tumor-bearing donors, provided that spleen cells were harvested from the donors on day 9 of tumor growth or later.
Tags: clone 53-6.72 of anti-mouse CD8a antibody; mouse CD8a antibody (clone 53-6.72)

For more references about anti-mouse CD8a antibody (53-6.72), please contact our scientific support team with message@sydlabs.com.

Syd Labs provides the following recombinant anti-human CD8a monoclonal antibodies:
In vivo grade recombinant anti-human CD8a antibodies (clone OKT8)
Recombinant anti-human CD8a antibodies (clone OKT8) for flow cytometry

Syd Labs provides the following recombinant anti-mouse CD8a monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8a antibodies (clone 2.43)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 169.4)
In vivo grade recombinant anti-mouse CD8a antibodies (clone YTS 105.18)

Syd Labs provides the following recombinant anti-mouse CD8b monoclonal antibodies:
In vivo grade recombinant anti-mouse CD8b antibodies (clone YTS 156.7)